Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors

Sara Monti, Monica Todoerti, Veronica Codullo, Ennio Giulio Favalli, Martina Biggioggero, Andrea Becciolini, Carlomaurizio Montecucco, Roberto Caporali

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Treat to target (T2T), aiming at inactive disease (ID), has become the recommended strategy for axial-SpA (ax-SpA). Using the Ankylosing Spondylitis Disease Activity Score (ASDAS), we assessed the prevalence of ID in ax-SpA patients treated with TNFα inhibitors (TNFi).

METHODS: A multicentric, cross-sectional study was performed assessing disease activity status (BASDAI and ASDAS) of consecutive patients with ax-SpA on stable treatment with TNFi for at least six months. We analyzed differences with nonradiographic axSpA (nr-ax-SpA) and the influence of population characteristics and comorbidities in reaching ID. ID was defined as ASDAS-CRP <1.3.

RESULTS: A total of 218 patients were enrolled, 165 with AS and 53 with nr-ax-SpA. ASDAS-CRP ID was reached by 89 (40.8%) patients, while 163 (74.8%) of patients achieved good disease control with BASDAI. There were no significant differences between the two diagnostic groups. Multivariate logistic regression demonstrated a negative correlation of concomitant fibromyalgia, higher BASMI and current NSAIDs with the chances of reaching ASDAS-CRP ID or BASDAI <4.

CONCLUSION: T2T represents a new challenge in the management of ax-SpA, with recently introduced disease activity measures being significantly more stringent. The prevalence of ID was affected by concomitant fibromyalgia, decreased spine mobility and concomitant NSAIDs.

Original languageEnglish
Pages (from-to)542-549
Number of pages8
JournalModern Rheumatology
Volume28
Issue number3
DOIs
Publication statusPublished - May 2018

Fingerprint

Ankylosing Spondylitis
Tumor Necrosis Factor-alpha
Fibromyalgia
Non-Steroidal Anti-Inflammatory Agents
Population Characteristics
Comorbidity

Keywords

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
  • Female
  • Fibromyalgia/epidemiology
  • Humans
  • Male
  • Middle Aged
  • Severity of Illness Index
  • Spondylitis, Ankylosing/drug therapy
  • Tumor Necrosis Factor-alpha/antagonists & inhibitors

Cite this

Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. / Monti, Sara; Todoerti, Monica; Codullo, Veronica; Favalli, Ennio Giulio; Biggioggero, Martina; Becciolini, Andrea; Montecucco, Carlomaurizio; Caporali, Roberto.

In: Modern Rheumatology, Vol. 28, No. 3, 05.2018, p. 542-549.

Research output: Contribution to journalArticle

@article{c410c053c435411da6d018ff54706aba,
title = "Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors",
abstract = "BACKGROUND: Treat to target (T2T), aiming at inactive disease (ID), has become the recommended strategy for axial-SpA (ax-SpA). Using the Ankylosing Spondylitis Disease Activity Score (ASDAS), we assessed the prevalence of ID in ax-SpA patients treated with TNFα inhibitors (TNFi).METHODS: A multicentric, cross-sectional study was performed assessing disease activity status (BASDAI and ASDAS) of consecutive patients with ax-SpA on stable treatment with TNFi for at least six months. We analyzed differences with nonradiographic axSpA (nr-ax-SpA) and the influence of population characteristics and comorbidities in reaching ID. ID was defined as ASDAS-CRP <1.3.RESULTS: A total of 218 patients were enrolled, 165 with AS and 53 with nr-ax-SpA. ASDAS-CRP ID was reached by 89 (40.8{\%}) patients, while 163 (74.8{\%}) of patients achieved good disease control with BASDAI. There were no significant differences between the two diagnostic groups. Multivariate logistic regression demonstrated a negative correlation of concomitant fibromyalgia, higher BASMI and current NSAIDs with the chances of reaching ASDAS-CRP ID or BASDAI <4.CONCLUSION: T2T represents a new challenge in the management of ax-SpA, with recently introduced disease activity measures being significantly more stringent. The prevalence of ID was affected by concomitant fibromyalgia, decreased spine mobility and concomitant NSAIDs.",
keywords = "Adult, Anti-Inflammatory Agents, Non-Steroidal/therapeutic use, Female, Fibromyalgia/epidemiology, Humans, Male, Middle Aged, Severity of Illness Index, Spondylitis, Ankylosing/drug therapy, Tumor Necrosis Factor-alpha/antagonists & inhibitors",
author = "Sara Monti and Monica Todoerti and Veronica Codullo and Favalli, {Ennio Giulio} and Martina Biggioggero and Andrea Becciolini and Carlomaurizio Montecucco and Roberto Caporali",
year = "2018",
month = "5",
doi = "10.1080/14397595.2017.1367076",
language = "English",
volume = "28",
pages = "542--549",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors

AU - Monti, Sara

AU - Todoerti, Monica

AU - Codullo, Veronica

AU - Favalli, Ennio Giulio

AU - Biggioggero, Martina

AU - Becciolini, Andrea

AU - Montecucco, Carlomaurizio

AU - Caporali, Roberto

PY - 2018/5

Y1 - 2018/5

N2 - BACKGROUND: Treat to target (T2T), aiming at inactive disease (ID), has become the recommended strategy for axial-SpA (ax-SpA). Using the Ankylosing Spondylitis Disease Activity Score (ASDAS), we assessed the prevalence of ID in ax-SpA patients treated with TNFα inhibitors (TNFi).METHODS: A multicentric, cross-sectional study was performed assessing disease activity status (BASDAI and ASDAS) of consecutive patients with ax-SpA on stable treatment with TNFi for at least six months. We analyzed differences with nonradiographic axSpA (nr-ax-SpA) and the influence of population characteristics and comorbidities in reaching ID. ID was defined as ASDAS-CRP <1.3.RESULTS: A total of 218 patients were enrolled, 165 with AS and 53 with nr-ax-SpA. ASDAS-CRP ID was reached by 89 (40.8%) patients, while 163 (74.8%) of patients achieved good disease control with BASDAI. There were no significant differences between the two diagnostic groups. Multivariate logistic regression demonstrated a negative correlation of concomitant fibromyalgia, higher BASMI and current NSAIDs with the chances of reaching ASDAS-CRP ID or BASDAI <4.CONCLUSION: T2T represents a new challenge in the management of ax-SpA, with recently introduced disease activity measures being significantly more stringent. The prevalence of ID was affected by concomitant fibromyalgia, decreased spine mobility and concomitant NSAIDs.

AB - BACKGROUND: Treat to target (T2T), aiming at inactive disease (ID), has become the recommended strategy for axial-SpA (ax-SpA). Using the Ankylosing Spondylitis Disease Activity Score (ASDAS), we assessed the prevalence of ID in ax-SpA patients treated with TNFα inhibitors (TNFi).METHODS: A multicentric, cross-sectional study was performed assessing disease activity status (BASDAI and ASDAS) of consecutive patients with ax-SpA on stable treatment with TNFi for at least six months. We analyzed differences with nonradiographic axSpA (nr-ax-SpA) and the influence of population characteristics and comorbidities in reaching ID. ID was defined as ASDAS-CRP <1.3.RESULTS: A total of 218 patients were enrolled, 165 with AS and 53 with nr-ax-SpA. ASDAS-CRP ID was reached by 89 (40.8%) patients, while 163 (74.8%) of patients achieved good disease control with BASDAI. There were no significant differences between the two diagnostic groups. Multivariate logistic regression demonstrated a negative correlation of concomitant fibromyalgia, higher BASMI and current NSAIDs with the chances of reaching ASDAS-CRP ID or BASDAI <4.CONCLUSION: T2T represents a new challenge in the management of ax-SpA, with recently introduced disease activity measures being significantly more stringent. The prevalence of ID was affected by concomitant fibromyalgia, decreased spine mobility and concomitant NSAIDs.

KW - Adult

KW - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use

KW - Female

KW - Fibromyalgia/epidemiology

KW - Humans

KW - Male

KW - Middle Aged

KW - Severity of Illness Index

KW - Spondylitis, Ankylosing/drug therapy

KW - Tumor Necrosis Factor-alpha/antagonists & inhibitors

U2 - 10.1080/14397595.2017.1367076

DO - 10.1080/14397595.2017.1367076

M3 - Article

C2 - 28880727

VL - 28

SP - 542

EP - 549

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 3

ER -